肾脏载脂蛋白C-II淀粉样变性的临床病理、蛋白质组学及结局特征:病例系列
该病例系列纳入25例经质谱诊断的肾脏载脂蛋白C-II淀粉样变性(AApoCII)患者,均为白人,多数为老年女性,表现为蛋白尿和肾功能下降,无其他器官受累。病理以结节性肾小球沉积为主,蛋白质组学常见Apo C-II变异(多为p.Lys41Thr)。平均随访75.5个月,约半数进展至终末期肾病,但总体生存较好。
要点
- AApoCII主要累及肾脏,多见于老年女性,表现为蛋白尿和慢性肾脏病。
- 肾活检多呈结节性肾小球淀粉样沉积,常无其他器官受累。
- 约半数患者随访期间进展至终末期肾病,但总体生存较优。
核心结论
- AApoCII主要累及肾脏,多见于老年人,表现为蛋白尿和慢性肾脏病,约半数进展至终末期肾病,但总体生存较优。
研究设计与样本
- 病例系列,纳入2008年1月至2024年1月Mayo Clinic组织蛋白质组学实验室 archives 中25例肾脏AApoCII病例。
主要发现
- 所有患者均为白人,19例诊断时≥65岁,18例为女性,7例有慢性肾脏病家族史。
- 患者表现为蛋白尿(中位数3.3g/天)和肾功能下降(n=16;肌酐中位数1.6mg/dL)。
- 所有病例肾小球均有淀粉样沉积(22例呈结节型),肾小球外受累较少且一般较轻。
- 蛋白质组学分析所有病例均检出丰富的Apo C-II及三种淀粉样标志蛋白(ApoE、ApoA-IV、SAP)谱,14例检出Apo C-II变异(12例K19T,2例E47V)。
- 22例有随访信息,平均随访75.5±12.5(SE)个月,发生12例终末期肾病事件和2例无终末期肾病死亡。
临床怎么用
- 对表现为蛋白尿和慢性肾脏病、肾活检呈结节性肾小球淀粉样沉积的老年患者,应考虑AApoCII并行质谱分型。
- AApoCII患者需监测肾功能,约半数可能进展至终末期肾病。
局限性
- 回顾性设计,样本量小,APOC2基因测序仅在较小亚组中进行。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RATIONALE & OBJECTIVE: Amyloidosis derived from apolipoprotein C-II (AApoCII) is a recently discovered, rare form of amyloidosis. Data on clinical presentations and natural history are very limited. This study defines the clinicopathologic, proteomic, and outcome characteristics of renal AApoCII. STUDY DESIGN: Case series. SETTING & PARTICIPANTS: Twenty-five renal AApoCII cases were identified from the Mayo Clinic Tissue Proteomics Laboratory archives from January 2008 through January 2024. FINDINGS: All patients were White, 19 were≥65 years old at diagnosis, and 18 were female. Seven had a family history of chronic kidney disease (CKD). Patients presented with proteinuria (median 3.3g/day) and reduced kidney function (n=16; median creatinine, 1.6mg/dL). No patients had clinical evidence of other organ involvement by amyloidosis or features of monogenic hypertriglyceridemia. Histologically, amyloid deposits were often weakly positive for Congo red and involved glomeruli in all cases (with a nodular pattern in 22), whereas extraglomerular involvement was less common and generally mild. Proteomic analysis revealed abundant spectra for Apo C-II and for all 3 amyloid signature proteins (apolipoprotein E, apolipoprotein A-IV, and serum amyloid P) in all cases and detected an Apo C-II variant in 14 (K19T [p.Lys41Thr] in 12 and E47V [p.Glu69Val] in 2). Among 22 patients with follow-up information available, there were 12 end-stage kidney disease (ESKD) events and 2 deaths without ESKD during an average follow-up period of 75.5±12.5 (SE) months. LIMITATIONS: Retrospective design, small sample size, APOC2 gene sequencing performed in a smaller subset. CONCLUSIONS: AApoCII mostly affects the kidney and manifests in the elderly with proteinuria and CKD. A minority of these patients had a family history of kidney disease. Kidney failure occurred in about half, whereas overall survival was more favorable. PLAIN-LANGUAGE SUMMARY: Amyloidosis derived from apolipoprotein C-II (AApoCII) is very rare, and data on clinicopathologic and outcome characteristics are scant. This study of 25 patients with AApoCII diagnosed by mass spectrometry at the Mayo Clinic Tissue Proteomics Laboratory revealed that most patients were elderly White females who presented with proteinuria and reduced kidney function, without involvement of other organs. A family history of kidney disease was often lacking. Pathologically, most cases exhibited nodular glomerular involvement. Proteomic analysis revealed abundant protein spectra for Apo C-II and amyloid signature proteins, and identified an Apo C-II variant in over half of cases (most commonly the p.Lys41Thr variant). The cumulative incidence of kidney failure was over 50% at 5 years follow-up. Only 4 deaths occurred over an average follow-up period of 76 months.
引用
- Nasr SH, Dasari S, Valeri AM, et al. Clinicopathologic, Proteomic and Outcome Characteristics of Renal Apolipoprotein C-II Amyloidosis: A Case Series. Am J Kidney Dis. 2024. PMID: 39547356. doi:10.1053/j.ajkd.2024.09.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。